Literature DB >> 8641988

Effect of MUC1 mucin, an anti-adhesion molecule, on tumor cell growth.

Y Makiguchi1, Y Hinoda, K Imai.   

Abstract

MUC1 mucin is expressed in a wide variety of tumors and is considered to function as an anti-adhesion molecule which inhibits cell-to-cell interactions. To reveal the biological significance of this activity in tumor cells, MUC1 cDNA was transfected into EJNIH3T3 cells and human colon cancer cell lines, CHCY1 and DLD1. The in vivo growth rate of MUC1+ (MUC1-transfected) EJNIH3T3, CHCY1 and DLD1 cells in SCID mice was clearly lower than that of MUC1- (mock transfectant) cells. Several in vitro experiments using MUC1+ EJNIH3T3 cells were performed to analyze the mechanisms for the decreased in vivo tumor growth. It was found that (i) the in vitro growth rate of MUC1+ EJNIH3T3 cells was also decreased compared to that of MUC1- cells, (ii)the DNA synthesis of MUC1+ EJNIH3T3 cells after stimulation with either growth factor (fetal calf serum or bombesin) or extracellular matrix (collagen or fibronectin) was lower than that of MUC1- cells, and (iii) MUC1+ EJNIH3T3 cells grew more slowly than MUC1- cells on both collagen- and fibronectin-coated dishes. These data suggest that MUC1 mucin may regulate tumor cell growth through inhibition of cell-to-cell, growth factor-to-receptor and cell-to-matrix interactions.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8641988      PMCID: PMC5921124          DOI: 10.1111/j.1349-7006.1996.tb00252.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


  34 in total

1.  Genetic manipulation of E-cadherin expression by epithelial tumor cells reveals an invasion suppressor role.

Authors:  K Vleminckx; L Vakaet; M Mareel; W Fiers; F van Roy
Journal:  Cell       Date:  1991-07-12       Impact factor: 41.582

2.  E-cadherin expression in squamous cell carcinomas of head and neck: inverse correlation with tumor dedifferentiation and lymph node metastasis.

Authors:  J H Schipper; U H Frixen; J Behrens; A Unger; K Jahnke; W Birchmeier
Journal:  Cancer Res       Date:  1991-12-01       Impact factor: 12.701

3.  Biliary glycoprotein, a member of the immunoglobulin supergene family, functions in vitro as a Ca2(+)-dependent intercellular adhesion molecule.

Authors:  M Rojas; A Fuks; C P Stanners
Journal:  Cell Growth Differ       Date:  1990-11

4.  Inhibition of mucin glycosylation by aryl-N-acetyl-alpha-galactosaminides in human colon cancer cells.

Authors:  S F Kuan; J C Byrd; C Basbaum; Y S Kim
Journal:  J Biol Chem       Date:  1989-11-15       Impact factor: 5.157

5.  Episialin (MUC1) inhibits cytotoxic lymphocyte-target cell interaction.

Authors:  E van de Wiel-van Kemenade; M J Ligtenberg; A J de Boer; F Buijs; H L Vos; C J Melief; J Hilkens; C G Figdor
Journal:  J Immunol       Date:  1993-07-15       Impact factor: 5.422

6.  Cell surface, heparin-like molecules are required for binding of basic fibroblast growth factor to its high affinity receptor.

Authors:  A Yayon; M Klagsbrun; J D Esko; P Leder; D M Ornitz
Journal:  Cell       Date:  1991-02-22       Impact factor: 41.582

7.  Bombesin, vasopressin, and endothelin stimulation of tyrosine phosphorylation in Swiss 3T3 cells. Identification of a novel tyrosine kinase as a major substrate.

Authors:  I Zachary; J Sinnett-Smith; E Rozengurt
Journal:  J Biol Chem       Date:  1992-09-25       Impact factor: 5.157

8.  Heterogeneity of mucin gene expression in normal and neoplastic tissues.

Authors:  S B Ho; G A Niehans; C Lyftogt; P S Yan; D L Cherwitz; E T Gum; R Dahiya; Y S Kim
Journal:  Cancer Res       Date:  1993-02-01       Impact factor: 12.701

9.  MUC1 mucin expression as a marker of progression and metastasis of human colorectal carcinoma.

Authors:  S Nakamori; D M Ota; K R Cleary; K Shirotani; T Irimura
Journal:  Gastroenterology       Date:  1994-02       Impact factor: 22.682

10.  Bombesin and bombesin antagonists: studies in Swiss 3T3 cells and human small cell lung cancer.

Authors:  P J Woll; E Rozengurt
Journal:  Br J Cancer       Date:  1988-06       Impact factor: 7.640

View more
  8 in total

1.  A cell surface mucin specifically expressed in the midgut of the malaria mosquito Anopheles gambiae.

Authors:  Z Shen; G Dimopoulos; F C Kafatos; M Jacobs-Lorena
Journal:  Proc Natl Acad Sci U S A       Date:  1999-05-11       Impact factor: 11.205

2.  Dysadherin, a cancer-associated cell membrane glycoprotein, down-regulates E-cadherin and promotes metastasis.

Authors:  Yoshinori Ino; Masahiro Gotoh; Michiie Sakamoto; Kiyomi Tsukagoshi; Setsuo Hirohashi
Journal:  Proc Natl Acad Sci U S A       Date:  2001-12-26       Impact factor: 11.205

3.  Absence of correlation of MUC1 expression to malignant behavior of renal cell carcinoma in experimental systems.

Authors:  K Denda-Nagai; K Fujita; M Fujime; S Nakatsugawa; T Ishigaki; T Irimura
Journal:  Clin Exp Metastasis       Date:  2000       Impact factor: 5.150

4.  Mucin expression in pleomorphic adenoma of salivary gland: a potential role for MUC1 as a marker to predict recurrence.

Authors:  T Hamada; S Matsukita; M Goto; S Kitajima; S K Batra; T Irimura; K Sueyoshi; K Sugihara; S Yonezawa
Journal:  J Clin Pathol       Date:  2004-08       Impact factor: 3.411

5.  Axed MUC4 (MUC4/X) aggravates pancreatic malignant phenotype by activating integrin-β1/FAK/ERK pathway.

Authors:  Rahat Jahan; Muzafar A Macha; Satyanarayana Rachagani; Srustidhar Das; Lynette M Smith; Sukhwinder Kaur; Surinder K Batra
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2018-05-16       Impact factor: 5.187

Review 6.  MUC1 in carcinoma-host interactions.

Authors:  K Denda-Nagai; T Irimura
Journal:  Glycoconj J       Date:  2000 Jul-Sep       Impact factor: 3.009

7.  Increased expression after X-irradiation of MUC1 in cultured human colon carcinoma HT-29 cells.

Authors:  Y Kang; K Hirano; N Suzuki; A Enomoto; A Morita; T Irimura; K Sakai
Journal:  Jpn J Cancer Res       Date:  2000-03

8.  Differential gene expression identifies KRT7 and MUC1 as potential metastasis-specific targets in sarcoma.

Authors:  Long Jiang; Bhairavi Tolani; Che-Chung Yeh; Yanying Fan; Joseph A Reza; Andrew E Horvai; Endi Xia; Johannes R Kratz; David M Jablons; Michael J Mann
Journal:  Cancer Manag Res       Date:  2019-09-09       Impact factor: 3.989

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.